Program
THRV-1268
A development code.
Its studies are mostly in Long QT Syndrome · Heart Failure · Atrial Fibrillation, led by Thryv Therapeutics.
Furthest: phase 3, since Dec 2, 20253 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Thryv Therapeutics | 31 open or running | phase 3since Dec 2, 2025 | Jul 11, 2024 | Jun 30, 2027phase 3 · NCT07277582 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2024First study: phase 1 study in Atrial FibrillationFirst studyNCT06507839 · 56 enrolled · Canada
- Sep 15, 2025Phase 1 study in Heart FailureNCT07186946 · 16 enrolled · United States
- Dec 2, 2025Phase 3 study in Long QT SyndromePhase 3 reachedNCT07277582 · 84 planned · United States
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Long QT SyndromeNCT07277582
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07277582Long QT Syndrome · United States | 3 | Recruiting | Jun 30, 2027 | 84 |
| NCT07186946Heart Failure · United States | 1 | Completed | Oct 20, 2025 | 16 |
| NCT06507839Atrial Fibrillation · Canada | 1 | Completed | Nov 1, 2024 | 56 |
How it is read
Names in the registry
- “THRV-1268”, 4 entries
Codes read as this program: THRV1268.
Conditions, from the studies’ own filings
- Long QT Syndrome, 1 study
- Heart Failure, 1 study
- Atrial Fibrillation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.